				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**23716**	**44**	**0.2**	**6**	**0.0**	**5**	**0.0**	**3**	**0.0**	**588**	**2.5**	**5688**	**24.3**	**3**	**0.0**	**9**	**0.0**	**137**	**0.6**
	Age at baseline	<18	5295	7	0.1	2	0.0	3	0.1	1	0.0	125	2.4	1613	30.8	1	0.0	3	0.1	68	1.3
		18-19	1964	6	0.3	.	.	1	0.1	.	.	46	2.4	613	31.7	.	.	2	0.1	11	0.6
		20-24	5511	10	0.2	3	0.1	1	0.0	1	0.0	109	2.0	1437	26.4	.	.	2	0.0	26	0.5
		25-29	5150	7	0.1	1	0.0	.	.	1	0.0	163	3.2	1134	22.3	1	0.0	1	0.0	17	0.3
		30-34	3566	7	0.2	.	.	.	.	.	.	93	2.6	614	17.5	.	.	1	0.0	11	0.3
		35+	2230	7	0.3	.	.	.	.	.	.	52	2.4	277	12.6	1	0.0	.	.	4	0.2
	Years since diagnosis	5-9	2391	6	0.3	2	0.1	.	.	1	0.0	83	3.5	615	26.2	.	.	5	0.2	18	0.8
		10-14	7681	17	0.2	3	0.0	4	0.1	1	0.0	195	2.6	2057	27.1	1	0.0	4	0.1	61	0.8
		15-19	7592	11	0.1	1	0.0	1	0.0	.	.	140	1.9	1803	24.1	1	0.0	.	.	46	0.6
		20+	6052	10	0.2	.	.	.	.	1	0.0	170	2.8	1213	20.3	1	0.0	.	.	12	0.2
	Age at diagnosis	<1	1789	6	0.3	1	0.1	1	0.1	.	.	28	1.6	135	7.6	1	0.1	.	.	15	0.8
		1-4	7646	10	0.1	.	.	4	0.1	1	0.0	151	2.0	2648	35.1	1	0.0	2	0.0	69	0.9
		5-9	5313	7	0.1	4	0.1	.	.	1	0.0	163	3.1	1426	27.1	.	.	1	0.0	23	0.4
		10-14	5026	8	0.2	1	0.0	.	.	1	0.0	166	3.3	1008	20.3	.	.	4	0.1	13	0.3
		15-20	3942	13	0.3	.	.	.	.	.	.	80	2.1	471	12.2	1	0.0	2	0.1	17	0.4
Males	**All cases**		**12555**	**18**	**0.1**	**3**	**0.0**	**3**	**0.0**	**2**	**0.0**	**341**	**2.7**	**2999**	**24.2**	**1**	**0.0**	**4**	**0.0**	**77**	**0.6**
	Age at baseline	<18	2844	2	0.1	2	0.1	1	0.0	.	.	74	2.6	835	29.8	.	.	1	0.0	44	1.6
		18-19	1013	3	0.3	.	.	1	0.1	.	.	30	3.0	322	32.2	.	.	1	0.1	8	0.8
		20-24	2866	6	0.2	1	0.0	1	0.0	1	0.0	53	1.9	713	25.2	.	.	1	0.0	11	0.4
		25-29	2820	3	0.1	.	.	.	.	1	0.0	110	3.9	627	22.5	.	.	1	0.0	5	0.2
		30-34	1889	2	0.1	.	.	.	.	.	.	48	2.6	333	17.9	.	.	.	.	7	0.4
		35+	1123	2	0.2	.	.	.	.	.	.	26	2.3	169	15.3	1	0.1	.	.	2	0.2
	Years since diagnosis	5-9	1331	4	0.3	1	0.1	.	.	1	0.1	52	4.0	328	25.1	.	.	3	0.2	10	0.8
		10-14	4084	6	0.1	2	0.0	2	0.0	.	.	118	2.9	1097	27.2	.	.	1	0.0	36	0.9
		15-19	3944	5	0.1	.	.	1	0.0	.	.	77	2.0	913	23.5	1	0.0	.	.	26	0.7
		20+	3196	3	0.1	.	.	.	.	1	0.0	94	3.0	661	20.9	.	.	.	.	5	0.2
	Age at diagnosis	<1	907	2	0.2	1	0.1	1	0.1	.	.	12	1.3	66	7.3	.	.	.	.	11	1.2
		1-4	3967	4	0.1	.	.	2	0.1	.	.	89	2.3	1345	34.4	.	.	.	.	38	1.0
		5-9	2975	3	0.1	2	0.1	.	.	1	0.0	99	3.4	770	26.3	.	.	1	0.0	15	0.5
		10-14	2625	5	0.2	.	.	.	.	1	0.0	97	3.7	533	20.5	.	.	2	0.1	5	0.2
		15-20	2081	4	0.2	.	.	.	.	.	.	44	2.1	285	13.9	1	0.0	1	0.0	8	0.4
Females	**All cases**		**11161**	**26**	**0.2**	**3**	**0.0**	**2**	**0.0**	**1**	**0.0**	**247**	**2.2**	**2689**	**24.4**	**2**	**0.0**	**5**	**0.0**	**60**	**0.5**
	Age at baseline	<18	2451	5	0.2	.	.	2	0.1	1	0.0	51	2.1	778	32.0	1	0.0	2	0.1	24	1.0
		18-19	951	3	0.3	.	.	.	.	.	.	16	1.7	291	31.2	.	.	1	0.1	3	0.3
		20-24	2645	4	0.2	2	0.1	.	.	.	.	56	2.1	724	27.7	.	.	1	0.0	15	0.6
		25-29	2330	4	0.2	1	0.0	.	.	.	.	53	2.3	507	22.0	1	0.0	.	.	12	0.5
		30-34	1677	5	0.3	.	.	.	.	.	.	45	2.7	281	17.0	.	.	1	0.1	4	0.2
		35+	1107	5	0.5	.	.	.	.	.	.	26	2.4	108	9.9	.	.	.	.	2	0.2
	Years since diagnosis	5-9	1060	2	0.2	1	0.1	.	.	.	.	31	2.9	287	27.5	.	.	2	0.2	8	0.8
		10-14	3597	11	0.3	1	0.0	2	0.1	1	0.0	77	2.2	960	26.9	1	0.0	3	0.1	25	0.7
		15-19	3648	6	0.2	1	0.0	.	.	.	.	63	1.7	890	24.7	.	.	.	.	20	0.6
		20+	2856	7	0.2	.	.	.	.	.	.	76	2.7	552	19.6	1	0.0	.	.	7	0.2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
	Age at diagnosis	<1	882	4	0.5	.	.	.	.	.	.	16	1.8	69	7.9	1	0.1	.	.	4	0.5
		1-4	3679	6	0.2	.	.	2	0.1	1	0.0	62	1.7	1303	35.9	1	0.0	2	0.1	31	0.8
		5-9	2338	4	0.2	2	0.1	.	.	.	.	64	2.8	656	28.3	.	.	.	.	8	0.3
		10-14	2401	3	0.1	1	0.0	.	.	.	.	69	2.9	475	20.0	.	.	2	0.1	8	0.3
		15-20	1861	9	0.5	.	.	.	.	.	.	36	2.0	186	10.2	.	.	1	0.1	9	0.5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**7302**	**43**	**0.6**	**.**	**.**	**3**	**0.0**	**3**	**0.0**	**199**	**2.7**	**5095**	**71.2**	**3**	**0.0**	**9**	**0.1**	**44**	**0.6**
	Age at baseline	<18	2099	7	0.3	.	.	2	0.1	1	0.0	39	1.9	1546	75.4	1	0.0	3	0.1	7	0.3
		18-19	769	6	0.8	.	.	1	0.1	.	.	15	2.0	566	75.5	.	.	2	0.3	4	0.5
		20-24	1799	10	0.6	.	.	.	.	1	0.1	35	2.0	1314	74.2	.	.	2	0.1	7	0.4
		25-29	1471	7	0.5	.	.	.	.	1	0.1	62	4.2	971	67.0	1	0.1	1	0.1	13	0.9
		30-34	779	7	0.9	.	.	.	.	.	.	25	3.3	470	62.4	.	.	1	0.1	10	1.3
		35+	385	6	1.6	.	.	.	.	.	.	23	6.1	228	60.3	1	0.3	.	.	3	0.8
	Years since diagnosis	5-9	906	6	0.7	.	.	.	.	1	0.1	28	3.1	571	64.8	.	.	5	0.6	2	0.2
		10-14	2444	17	0.7	.	.	3	0.1	1	0.0	74	3.1	1871	78.2	1	0.0	4	0.2	19	0.8
		15-19	2246	10	0.4	.	.	.	.	.	.	43	1.9	1579	71.7	1	0.0	.	.	19	0.9
		20+	1706	10	0.6	.	.	.	.	1	0.1	54	3.2	1074	64.1	1	0.1	.	.	4	0.2
	Age at diagnosis	<1	233	6	2.6	.	.	.	.	.	.	5	2.2	132	58.1	1	0.4	.	.	3	1.3
		1-4	3449	10	0.3	.	.	3	0.1	1	0.0	55	1.6	2529	74.8	1	0.0	2	0.1	12	0.3
		5-9	1767	7	0.4	.	.	.	.	1	0.1	41	2.3	1254	72.5	.	.	1	0.1	4	0.2
		10-14	1216	8	0.7	.	.	.	.	1	0.1	62	5.1	817	68.3	.	.	4	0.3	11	0.9
		15-20	637	12	1.9	.	.	.	.	.	.	36	5.8	363	58.9	1	0.2	2	0.3	14	2.2
Males	**All cases**		**3855**	**18**	**0.5**	**.**	**.**	**1**	**0.0**	**2**	**0.1**	**108**	**2.8**	**2622**	**69.6**	**1**	**0.0**	**4**	**0.1**	**21**	**0.5**
	Age at baseline	<18	1137	2	0.2	.	.	.	.	.	.	22	1.9	788	71.4	.	.	1	0.1	3	0.3
		18-19	410	3	0.7	.	.	1	0.2	.	.	8	2.0	291	72.2	.	.	1	0.2	2	0.5
		20-24	895	6	0.7	.	.	.	.	1	0.1	13	1.5	635	72.0	.	.	1	0.1	4	0.4
		25-29	788	3	0.4	.	.	.	.	1	0.1	42	5.4	522	67.6	.	.	1	0.1	3	0.4
		30-34	411	2	0.5	.	.	.	.	.	.	13	3.3	245	62.0	.	.	.	.	7	1.8
		35+	214	2	0.9	.	.	.	.	.	.	10	4.7	141	66.8	1	0.5	.	.	2	0.9
	Years since diagnosis	5-9	510	4	0.8	.	.	.	.	1	0.2	15	3.0	290	58.5	.	.	3	0.6	2	0.4
		10-14	1300	6	0.5	.	.	1	0.1	.	.	44	3.4	977	77.2	.	.	1	0.1	8	0.6
		15-19	1138	5	0.4	.	.	.	.	.	.	21	1.9	778	69.8	1	0.1	.	.	9	0.8
		20+	907	3	0.3	.	.	.	.	1	0.1	28	3.1	577	64.8	.	.	.	.	2	0.2
	Age at diagnosis	<1	111	2	1.8	.	.	.	.	.	.	2	1.8	66	62.3	.	.	.	.	1	0.9
		1-4	1822	4	0.2	.	.	1	0.1	.	.	31	1.7	1269	70.9	.	.	.	.	6	0.3
		5-9	942	3	0.3	.	.	.	.	1	0.1	24	2.6	655	71.5	.	.	1	0.1	2	0.2
		10-14	596	5	0.8	.	.	.	.	1	0.2	29	4.9	408	69.9	.	.	2	0.3	4	0.7
		15-20	384	4	1.1	.	.	.	.	.	.	22	5.9	224	60.2	1	0.3	1	0.3	8	2.1
Females	**All cases**		**3447**	**25**	**0.7**	**.**	**.**	**2**	**0.1**	**1**	**0.0**	**91**	**2.7**	**2473**	**73.1**	**2**	**0.1**	**5**	**0.1**	**23**	**0.7**
	Age at baseline	<18	962	5	0.5	.	.	2	0.2	1	0.1	17	1.8	758	80.0	1	0.1	2	0.2	4	0.4
		18-19	359	3	0.8	.	.	.	.	.	.	7	2.0	275	79.3	.	.	1	0.3	2	0.6
		20-24	904	4	0.4	.	.	.	.	.	.	22	2.4	679	76.5	.	.	1	0.1	3	0.3
		25-29	683	4	0.6	.	.	.	.	.	.	20	2.9	449	66.2	1	0.1	.	.	10	1.5
		30-34	368	5	1.4	.	.	.	.	.	.	12	3.3	225	62.8	.	.	1	0.3	3	0.8
		35+	171	4	2.4	.	.	.	.	.	.	13	7.7	87	52.1	.	.	.	.	1	0.6
	Years since diagnosis	5-9	396	2	0.5	.	.	.	.	.	.	13	3.3	281	73.0	.	.	2	0.5	.	.
		10-14	1144	11	1.0	.	.	2	0.2	1	0.1	30	2.6	894	79.3	1	0.1	3	0.3	11	1.0
		15-19	1108	5	0.5	.	.	.	.	.	.	22	2.0	801	73.6	.	.	.	.	10	0.9
		20+	799	7	0.9	.	.	.	.	.	.	26	3.3	497	63.3	1	0.1	.	.	2	0.3
	Age at diagnosis	<1	122	4	3.3	.	.	.	.	.	.	3	2.5	66	54.5	1	0.8	.	.	2	1.6
		1-4	1627	6	0.4	.	.	2	0.1	1	0.1	24	1.5	1260	79.1	1	0.1	2	0.1	6	0.4
		5-9	825	4	0.5	.	.	.	.	.	.	17	2.1	599	73.6	.	.	.	.	2	0.2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	620	3	0.5	.	.	.	.	.	.	33	5.3	409	66.7	.	.	2	0.3	7	1.1
		15-20	253	8	3.2	.	.	.	.	.	.	14	5.7	139	57.0	.	.	1	0.4	6	2.4

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**6109**	**3**	**0.0**	**.**	**.**	**2**	**0.0**	**2**	**0.0**	**98**	**1.6**	**4809**	**80.4**	**2**	**0.0**	**.**	**.**	**.**	**.**
	Age at baseline	<18	1814	1	0.1	.	.	1	0.1	1	0.1	25	1.4	1454	82.1	.	.	.	.	.	.
		18-19	666	.	.	.	.	1	0.2	.	.	9	1.4	538	83.0	.	.	.	.	.	.
		20-24	1532	.	.	.	.	.	.	.	.	15	1.0	1242	82.5	.	.	.	.	.	.
		25-29	1217	1	0.1	.	.	.	.	1	0.1	36	3.0	924	76.9	1	0.1	.	.	.	.
		30-34	604	1	0.2	.	.	.	.	.	.	6	1.0	438	75.0	.	.	.	.	.	.
		35+	276	.	.	.	.	.	.	.	.	7	2.6	213	78.9	1	0.4	.	.	.	.
	Years since diagnosis	5-9	778	.	.	.	.	.	.	.	.	16	2.1	535	70.8	.	.	.	.	.	.
		10-14	2048	3	0.1	.	.	2	0.1	1	0.0	40	2.0	1764	88.1	.	.	.	.	.	.
		15-19	1853	.	.	.	.	.	.	.	.	13	0.7	1505	82.9	1	0.1	.	.	.	.
		20+	1430	.	.	.	.	.	.	1	0.1	29	2.0	1005	71.5	1	0.1	.	.	.	.
	Age at diagnosis	<1	128	.	.	.	.	.	.	.	.	3	2.4	102	81.6	.	.	.	.	.	.
		1-4	3055	1	0.0	.	.	2	0.1	1	0.0	31	1.0	2413	80.7	1	0.0	.	.	.	.
		5-9	1545	.	.	.	.	.	.	1	0.1	29	1.9	1191	78.8	.	.	.	.	.	.
		10-14	949	.	.	.	.	.	.	.	.	25	2.6	767	81.8	.	.	.	.	.	.
		15-20	432	2	0.5	.	.	.	.	.	.	10	2.4	336	81.2	1	0.2	.	.	.	.
Males	**All cases**		**3252**	**.**	**.**	**.**	**.**	**1**	**0.0**	**1**	**0.0**	**64**	**2.0**	**2468**	**77.6**	**1**	**0.0**	**.**	**.**	**.**	**.**
	Age at baseline	<18	982	.	.	.	.	.	.	.	.	17	1.7	738	77.4	.	.	.	.	.	.
		18-19	358	.	.	.	.	1	0.3	.	.	6	1.7	274	78.1	.	.	.	.	.	.
		20-24	762	.	.	.	.	.	.	.	.	5	0.7	599	79.8	.	.	.	.	.	.
		25-29	665	.	.	.	.	.	.	1	0.2	27	4.1	496	75.8	.	.	.	.	.	.
		30-34	324	.	.	.	.	.	.	.	.	5	1.6	228	73.1	.	.	.	.	.	.
		35+	161	.	.	.	.	.	.	.	.	4	2.5	133	83.6	1	0.6	.	.	.	.
	Years since diagnosis	5-9	439	.	.	.	.	.	.	.	.	11	2.5	273	63.9	.	.	.	.	.	.
		10-14	1098	.	.	.	.	1	0.1	.	.	26	2.4	916	85.7	.	.	.	.	.	.
		15-19	950	.	.	.	.	.	.	.	.	9	1.0	739	79.4	1	0.1	.	.	.	.
		20+	765	.	.	.	.	.	.	1	0.1	18	2.4	540	71.7	.	.	.	.	.	.
	Age at diagnosis	<1	64	.	.	.	.	.	.	.	.	1	1.6	51	82.3	.	.	.	.	.	.
		1-4	1603	.	.	.	.	1	0.1	.	.	19	1.2	1202	76.5	.	.	.	.	.	.
		5-9	833	.	.	.	.	.	.	1	0.1	21	2.5	627	77.3	.	.	.	.	.	.
		10-14	483	.	.	.	.	.	.	.	.	15	3.1	382	80.1	.	.	.	.	.	.
		15-20	269	.	.	.	.	.	.	.	.	8	3.1	206	79.5	1	0.4	.	.	.	.
Females	**All cases**		**2857**	**3**	**0.1**	**.**	**.**	**1**	**0.0**	**1**	**0.0**	**34**	**1.2**	**2341**	**83.6**	**1**	**0.0**	**.**	**.**	**.**	**.**
	Age at baseline	<18	832	1	0.1	.	.	1	0.1	1	0.1	8	1.0	716	87.6	.	.	.	.	.	.
		18-19	308	.	.	.	.	.	.	.	.	3	1.0	264	88.9	.	.	.	.	.	.
		20-24	770	.	.	.	.	.	.	.	.	10	1.3	643	85.2	.	.	.	.	.	.
		25-29	552	1	0.2	.	.	.	.	.	.	9	1.6	428	78.2	1	0.2	.	.	.	.
		30-34	280	1	0.4	.	.	.	.	.	.	1	0.4	210	77.2	.	.	.	.	.	.
		35+	115	.	.	.	.	.	.	.	.	3	2.7	80	72.1	.	.	.	.	.	.
	Years since diagnosis	5-9	339	.	.	.	.	.	.	.	.	5	1.5	262	79.6	.	.	.	.	.	.
		10-14	950	3	0.3	.	.	1	0.1	1	0.1	14	1.5	848	90.8	.	.	.	.	.	.
		15-19	903	.	.	.	.	.	.	.	.	4	0.4	766	86.7	.	.	.	.	.	.
		20+	665	.	.	.	.	.	.	.	.	11	1.7	465	71.3	1	0.2	.	.	.	.
	Age at diagnosis	<1	64	.	.	.	.	.	.	.	.	2	3.1	51	81.0	.	.	.	.	.	.
		1-4	1452	1	0.1	.	.	1	0.1	1	0.1	12	0.8	1211	85.3	1	0.1	.	.	.	.
		5-9	712	.	.	.	.	.	.	.	.	8	1.1	564	80.5	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	466	.	.	.	.	.	.	.	.	10	2.2	385	83.5	.	.	.	.	.	.
		15-20	163	2	1.3	.	.	.	.	.	.	2	1.3	130	83.9	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**882**	**40**	**4.6**	**.**	**.**	**1**	**0.1**	**1**	**0.1**	**18**	**2.1**	**205**	**23.6**	**.**	**.**	**.**	**.**	**38**	**4.4**
	Age at baseline	<18	225	6	2.7	.	.	1	0.4	.	.	4	1.8	76	34.1	.	.	.	.	4	1.8
		18-19	82	6	7.4	.	.	.	.	.	.	1	1.2	22	27.2	.	.	.	.	4	4.9
		20-24	193	10	5.2	.	.	.	.	1	0.5	5	2.6	45	23.7	.	.	.	.	6	3.1
		25-29	188	6	3.2	.	.	.	.	.	.	3	1.6	34	18.2	.	.	.	.	12	6.4
		30-34	121	6	5.0	.	.	.	.	.	.	3	2.5	20	17.1	.	.	.	.	10	8.4
		35+	73	6	8.3	.	.	.	.	.	.	2	2.8	8	11.1	.	.	.	.	2	2.8
	Years since diagnosis	5-9	81	6	7.6	.	.	.	.	1	1.3	.	.	28	35.9	.	.	.	.	1	1.3
		10-14	307	14	4.6	.	.	1	0.3	.	.	6	2.0	85	28.0	.	.	.	.	16	5.3
		15-19	304	10	3.3	.	.	.	.	.	.	4	1.3	50	16.6	.	.	.	.	18	5.9
		20+	190	10	5.3	.	.	.	.	.	.	8	4.3	42	22.6	.	.	.	.	3	1.6
	Age at diagnosis	<1	90	6	6.7	.	.	.	.	.	.	1	1.1	28	31.5	.	.	.	.	1	1.1
		1-4	301	9	3.0	.	.	1	0.3	.	.	10	3.3	82	27.3	.	.	.	.	10	3.3
		5-9	166	7	4.2	.	.	.	.	.	.	.	.	43	26.4	.	.	.	.	4	2.4
		10-14	186	8	4.4	.	.	.	.	1	0.5	3	1.6	35	19.3	.	.	.	.	10	5.5
		15-20	139	10	7.2	.	.	.	.	.	.	4	2.9	17	12.4	.	.	.	.	13	9.4
Males	**All cases**		**430**	**18**	**4.2**	**.**	**.**	**.**	**.**	**1**	**0.2**	**11**	**2.6**	**99**	**23.5**	**.**	**.**	**.**	**.**	**18**	**4.2**
	Age at baseline	<18	122	2	1.7	.	.	.	.	.	.	3	2.5	41	34.2	.	.	.	.	2	1.7
		18-19	42	3	7.1	.	.	.	.	.	.	1	2.4	14	33.3	.	.	.	.	2	4.8
		20-24	92	6	6.6	.	.	.	.	1	1.1	3	3.3	16	17.8	.	.	.	.	3	3.3
		25-29	82	3	3.7	.	.	.	.	.	.	2	2.5	17	21.0	.	.	.	.	3	3.7
		30-34	58	2	3.5	.	.	.	.	.	.	2	3.5	9	16.4	.	.	.	.	7	12.3
		35+	34	2	6.1	.	.	.	.	.	.	.	.	2	6.1	.	.	.	.	1	3.0
	Years since diagnosis	5-9	47	4	8.7	.	.	.	.	1	2.1	.	.	12	26.7	.	.	.	.	1	2.1
		10-14	152	6	4.0	.	.	.	.	.	.	5	3.3	47	31.5	.	.	.	.	8	5.4
		15-19	141	5	3.5	.	.	.	.	.	.	3	2.1	23	16.4	.	.	.	.	8	5.7
		20+	90	3	3.4	.	.	.	.	.	.	3	3.4	17	19.5	.	.	.	.	1	1.1
	Age at diagnosis	<1	39	2	5.3	.	.	.	.	.	.	1	2.6	15	39.5	.	.	.	.	1	2.6
		1-4	165	4	2.4	.	.	.	.	.	.	7	4.2	44	26.7	.	.	.	.	4	2.4
		5-9	76	3	4.0	.	.	.	.	.	.	.	.	15	20.5	.	.	.	.	2	2.7
		10-14	75	5	6.8	.	.	.	.	1	1.4	1	1.4	15	20.8	.	.	.	.	4	5.5
		15-20	75	4	5.4	.	.	.	.	.	.	2	2.7	10	13.7	.	.	.	.	7	9.3
Females	**All cases**		**452**	**22**	**4.9**	**.**	**.**	**1**	**0.2**	**.**	**.**	**7**	**1.6**	**106**	**23.6**	**.**	**.**	**.**	**.**	**20**	**4.5**
	Age at baseline	<18	103	4	3.9	.	.	1	1.0	.	.	1	1.0	35	34.0	.	.	.	.	2	2.0
		18-19	40	3	7.7	.	.	.	.	.	.	.	.	8	20.5	.	.	.	.	2	5.1
		20-24	101	4	4.0	.	.	.	.	.	.	2	2.0	29	29.0	.	.	.	.	3	3.0
		25-29	106	3	2.8	.	.	.	.	.	.	1	0.9	17	16.0	.	.	.	.	9	8.5
		30-34	63	4	6.5	.	.	.	.	.	.	1	1.6	11	17.7	.	.	.	.	3	4.8
		35+	39	4	10.3	.	.	.	.	.	.	2	5.1	6	15.4	.	.	.	.	1	2.6
	Years since diagnosis	5-9	34	2	6.1	.	.	.	.	.	.	.	.	16	48.5	.	.	.	.	.	.
		10-14	155	8	5.2	.	.	1	0.6	.	.	1	0.6	38	24.5	.	.	.	.	8	5.2
		15-19	163	5	3.1	.	.	.	.	.	.	1	0.6	27	16.7	.	.	.	.	10	6.2
		20+	100	7	7.1	.	.	.	.	.	.	5	5.1	25	25.3	.	.	.	.	2	2.0
	Age at diagnosis	<1	51	4	7.8	.	.	.	.	.	.	.	.	13	25.5	.	.	.	.	.	.
		1-4	136	5	3.7	.	.	1	0.7	.	.	3	2.2	38	28.1	.	.	.	.	6	4.5
		5-9	90	4	4.4	.	.	.	.	.	.	.	.	28	31.1	.	.	.	.	2	2.2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	111	3	2.8	.	.	.	.	.	.	2	1.8	20	18.3	.	.	.	.	6	5.5
		15-20	64	6	9.4	.	.	.	.	.	.	2	3.1	7	10.9	.	.	.	.	6	9.4

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**4211**	**.**	**.**	**5**	**0.1**	**.**	**.**	**.**	**.**	**164**	**3.9**	**2**	**0.0**	**.**	**.**	**.**	**.**	**5**	**0.1**
	Age at baseline	<18	891	.	.	2	0.2	.	.	.	.	51	5.8	.	.	.	.	.	.	2	0.2
		18-19	349	.	.	.	.	.	.	.	.	10	2.9	.	.	.	.	.	.	1	0.3
		20-24	1103	.	.	2	0.2	.	.	.	.	31	2.8	2	0.2	.	.	.	.	.	.
		25-29	1029	.	.	1	0.1	.	.	.	.	42	4.1	.	.	.	.	.	.	2	0.2
		30-34	586	.	.	.	.	.	.	.	.	22	3.8	.	.	.	.	.	.	.	.
		35+	253	.	.	.	.	.	.	.	.	8	3.2	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	430	.	.	1	0.2	.	.	.	.	37	8.8	.	.	.	.	.	.	.	.
		10-14	1427	.	.	3	0.2	.	.	.	.	49	3.5	1	0.1	.	.	.	.	3	0.2
		15-19	1335	.	.	1	0.1	.	.	.	.	20	1.5	1	0.1	.	.	.	.	2	0.2
		20+	1019	.	.	.	.	.	.	.	.	58	5.7	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	206	.	.	1	0.5	.	.	.	.	12	5.9	.	.	.	.	.	.	2	1.0
		1-4	1231	.	.	.	.	.	.	.	.	49	4.0	1	0.1	.	.	.	.	1	0.1
		5-9	1331	.	.	4	0.3	.	.	.	.	58	4.4	1	0.1	.	.	.	.	1	0.1
		10-14	1005	.	.	.	.	.	.	.	.	34	3.4	.	.	.	.	.	.	1	0.1
		15-20	438	.	.	.	.	.	.	.	.	11	2.6	.	.	.	.	.	.	.	.
Males	**All cases**		**2292**	**.**	**.**	**3**	**0.1**	**.**	**.**	**.**	**.**	**92**	**4.1**	**2**	**0.1**	**.**	**.**	**.**	**.**	**3**	**0.1**
	Age at baseline	<18	494	.	.	2	0.4	.	.	.	.	35	7.2	.	.	.	.	.	.	1	0.2
		18-19	177	.	.	.	.	.	.	.	.	5	2.9	.	.	.	.	.	.	1	0.6
		20-24	590	.	.	1	0.2	.	.	.	.	14	2.4	2	0.3	.	.	.	.	.	.
		25-29	584	.	.	.	.	.	.	.	.	28	4.8	.	.	.	.	.	.	1	0.2
		30-34	312	.	.	.	.	.	.	.	.	8	2.6	.	.	.	.	.	.	.	.
		35+	135	.	.	.	.	.	.	.	.	2	1.6	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	244	.	.	1	0.4	.	.	.	.	23	9.7	.	.	.	.	.	.	.	.
		10-14	768	.	.	2	0.3	.	.	.	.	31	4.1	1	0.1	.	.	.	.	2	0.3
		15-19	726	.	.	.	.	.	.	.	.	9	1.3	1	0.1	.	.	.	.	1	0.1
		20+	554	.	.	.	.	.	.	.	.	29	5.3	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	121	.	.	1	0.8	.	.	.	.	8	6.7	.	.	.	.	.	.	2	1.7
		1-4	652	.	.	.	.	.	.	.	.	27	4.2	1	0.2	.	.	.	.	.	.
		5-9	741	.	.	2	0.3	.	.	.	.	34	4.7	1	0.1	.	.	.	.	.	.
		10-14	531	.	.	.	.	.	.	.	.	17	3.3	.	.	.	.	.	.	1	0.2
		15-20	247	.	.	.	.	.	.	.	.	6	2.5	.	.	.	.	.	.	.	.
Females	**All cases**		**1919**	**.**	**.**	**2**	**0.1**	**.**	**.**	**.**	**.**	**72**	**3.8**	**.**	**.**	**.**	**.**	**.**	**.**	**2**	**0.1**
	Age at baseline	<18	397	.	.	.	.	.	.	.	.	16	4.0	.	.	.	.	.	.	1	0.3
		18-19	172	.	.	.	.	.	.	.	.	5	3.0	.	.	.	.	.	.	.	.
		20-24	513	.	.	1	0.2	.	.	.	.	17	3.4	.	.	.	.	.	.	.	.
		25-29	445	.	.	1	0.2	.	.	.	.	14	3.2	.	.	.	.	.	.	1	0.2
		30-34	274	.	.	.	.	.	.	.	.	14	5.1	.	.	.	.	.	.	.	.
		35+	118	.	.	.	.	.	.	.	.	6	5.1	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	186	.	.	.	.	.	.	.	.	14	7.6	.	.	.	.	.	.	.	.
		10-14	659	.	.	1	0.2	.	.	.	.	18	2.8	.	.	.	.	.	.	1	0.2
		15-19	609	.	.	1	0.2	.	.	.	.	11	1.8	.	.	.	.	.	.	1	0.2
		20+	465	.	.	.	.	.	.	.	.	29	6.3	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	85	.	.	.	.	.	.	.	.	4	4.7	.	.	.	.	.	.	.	.
		1-4	579	.	.	.	.	.	.	.	.	22	3.8	.	.	.	.	.	.	1	0.2
		5-9	590	.	.	2	0.3	.	.	.	.	24	4.1	.	.	.	.	.	.	1	0.2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	474	.	.	.	.	.	.	.	.	17	3.6	.	.	.	.	.	.	.	.
		15-20	191	.	.	.	.	.	.	.	.	5	2.7	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2528**	.	.	**4**	**0.2**	.	.	.	.	**59**	**2.4**	**1**	**0.0**	.	.	.	.	**3**	**0.1**
	Age at baseline	<18	493	.	.	2	0.4	.	.	.	.	17	3.5	.	.	.	.	.	.	.	.
		18-19	202	.	.	.	.	.	.	.	.	3	1.5	.	.	.	.	.	.	1	0.5
		20-24	668	.	.	2	0.3	.	.	.	.	10	1.5	1	0.2	.	.	.	.	.	.
		25-29	636	.	.	.	.	.	.	.	.	19	3.0	.	.	.	.	.	.	2	0.3
		30-34	360	.	.	.	.	.	.	.	.	9	2.5	.	.	.	.	.	.	.	.
		35+	169	.	.	.	.	.	.	.	.	1	0.6	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	220	.	.	1	0.5	.	.	.	.	11	5.0	.	.	.	.	.	.	.	.
		10-14	840	.	.	3	0.4	.	.	.	.	24	2.9	1	0.1	.	.	.	.	1	0.1
		15-19	784	.	.	.	.	.	.	.	.	5	0.6	.	.	.	.	.	.	2	0.3
		20+	684	.	.	.	.	.	.	.	.	19	2.8	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	145	.	.	1	0.7	.	.	.	.	7	4.8	.	.	.	.	.	.	1	0.7
		1-4	748	.	.	.	.	.	.	.	.	9	1.2	.	.	.	.	.	.	.	.
		5-9	753	.	.	3	0.4	.	.	.	.	23	3.1	1	0.1	.	.	.	.	1	0.1
		10-14	603	.	.	.	.	.	.	.	.	14	2.3	.	.	.	.	.	.	1	0.2
		15-20	279	.	.	.	.	.	.	.	.	6	2.2	.	.	.	.	.	.	.	.
Males	**All cases**		**1315**	.	.	**3**	**0.2**	.	.	.	.	**38**	**2.9**	**1**	**0.1**	.	.	.	.	**2**	**0.2**
	Age at baseline	<18	258	.	.	2	0.8	.	.	.	.	15	5.9	.	.	.	.	.	.	.	.
		18-19	102	.	.	.	.	.	.	.	.	3	3.0	.	.	.	.	.	.	1	1.0
		20-24	329	.	.	1	0.3	.	.	.	.	5	1.5	1	0.3	.	.	.	.	.	.
		25-29	356	.	.	.	.	.	.	.	.	12	3.4	.	.	.	.	.	.	1	0.3
		30-34	181	.	.	.	.	.	.	.	.	3	1.7	.	.	.	.	.	.	.	.
		35+	89	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	118	.	.	1	0.8	.	.	.	.	8	6.8	.	.	.	.	.	.	.	.
		10-14	438	.	.	2	0.5	.	.	.	.	19	4.4	1	0.2	.	.	.	.	1	0.2
		15-19	396	.	.	.	.	.	.	.	.	3	0.8	.	.	.	.	.	.	1	0.3
		20+	363	.	.	.	.	.	.	.	.	8	2.2	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	81	.	.	1	1.2	.	.	.	.	6	7.4	.	.	.	.	.	.	1	1.2
		1-4	378	.	.	.	.	.	.	.	.	6	1.6	.	.	.	.	.	.	.	.
		5-9	397	.	.	2	0.5	.	.	.	.	15	3.8	1	0.3	.	.	.	.	.	.
		10-14	304	.	.	.	.	.	.	.	.	8	2.6	.	.	.	.	.	.	1	0.3
		15-20	155	.	.	.	.	.	.	.	.	3	2.0	.	.	.	.	.	.	.	.
Females	**All cases**		**1213**	.	.	**1**	**0.1**	.	.	.	.	**21**	**1.7**	.	.	.	.	.	.	**1**	**0.1**
	Age at baseline	<18	235	.	.	.	.	.	.	.	.	2	0.9	.	.	.	.	.	.	.	.
		18-19	100	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	339	.	.	1	0.3	.	.	.	.	5	1.5	.	.	.	.	.	.	.	.
		25-29	280	.	.	.	.	.	.	.	.	7	2.5	.	.	.	.	.	.	1	0.4
		30-34	179	.	.	.	.	.	.	.	.	6	3.4	.	.	.	.	.	.	.	.
		35+	80	.	.	.	.	.	.	.	.	1	1.3	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	102	.	.	.	.	.	.	.	.	3	3.0	.	.	.	.	.	.	.	.
		10-14	402	.	.	1	0.3	.	.	.	.	5	1.3	.	.	.	.	.	.	.	.
		15-19	388	.	.	.	.	.	.	.	.	2	0.5	.	.	.	.	.	.	1	0.3
		20+	321	.	.	.	.	.	.	.	.	11	3.4	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	64	.	.	.	.	.	.	.	.	1	1.6	.	.	.	.	.	.	.	.
		1-4	370	.	.	.	.	.	.	.	.	3	0.8	.	.	.	.	.	.	.	.
		5-9	356	.	.	1	0.3	.	.	.	.	8	2.3	.	.	.	.	.	.	1	0.3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	299	.	.	.	.	.	.	.	.	6	2.0	.	.	.	.	.	.	.	.
		15-20	124	.	.	.	.	.	.	.	.	3	2.5	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**983**	**.**	**.**	**1**	**0.1**	**.**	**.**	**.**	**.**	**87**	**9.0**	**1**	**0.1**	**.**	**.**	**.**	**.**	**1**	**0.1**
	Age at baseline	<18	233	.	.	.	.	.	.	.	.	27	11.7	.	.	.	.	.	.	1	0.4
		18-19	77	.	.	.	.	.	.	.	.	5	6.8	.	.	.	.	.	.	.	.
		20-24	276	.	.	.	.	.	.	.	.	16	5.9	1	0.4	.	.	.	.	.	.
		25-29	236	.	.	1	0.4	.	.	.	.	19	8.1	.	.	.	.	.	.	.	.
		30-34	127	.	.	.	.	.	.	.	.	13	10.3	.	.	.	.	.	.	.	.
		35+	34	.	.	.	.	.	.	.	.	7	21.9	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	120	.	.	.	.	.	.	.	.	20	17.2	.	.	.	.	.	.	.	.
		10-14	334	.	.	.	.	.	.	.	.	22	6.7	.	.	.	.	.	.	1	0.3
		15-19	325	.	.	1	0.3	.	.	.	.	13	4.0	1	0.3	.	.	.	.	.	.
		20+	204	.	.	.	.	.	.	.	.	32	15.9	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	23	.	.	.	.	.	.	.	.	2	9.1	.	.	.	.	.	.	1	4.5
		1-4	280	.	.	.	.	.	.	.	.	30	10.9	1	0.4	.	.	.	.	.	.
		5-9	402	.	.	1	0.3	.	.	.	.	31	7.8	.	.	.	.	.	.	.	.
		10-14	220	.	.	.	.	.	.	.	.	20	9.3	.	.	.	.	.	.	.	.
		15-20	58	.	.	.	.	.	.	.	.	4	7.3	.	.	.	.	.	.	.	.
Males	**All cases**		**600**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**49**	**8.3**	**1**	**0.2**	**.**	**.**	**.**	**.**	**1**	**0.2**
	Age at baseline	<18	141	.	.	.	.	.	.	.	.	19	13.8	.	.	.	.	.	.	1	0.7
		18-19	44	.	.	.	.	.	.	.	.	1	2.4	.	.	.	.	.	.	.	.
		20-24	178	.	.	.	.	.	.	.	.	7	4.0	1	0.6	.	.	.	.	.	.
		25-29	145	.	.	.	.	.	.	.	.	15	10.4	.	.	.	.	.	.	.	.
		30-34	71	.	.	.	.	.	.	.	.	5	7.1	.	.	.	.	.	.	.	.
		35+	21	.	.	.	.	.	.	.	.	2	10.5	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	73	.	.	.	.	.	.	.	.	13	18.8	.	.	.	.	.	.	.	.
		10-14	197	.	.	.	.	.	.	.	.	12	6.2	.	.	.	.	.	.	1	0.5
		15-19	207	.	.	.	.	.	.	.	.	5	2.4	1	0.5	.	.	.	.	.	.
		20+	123	.	.	.	.	.	.	.	.	19	15.8	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	16	.	.	.	.	.	.	.	.	2	13.3	.	.	.	.	.	.	1	6.7
		1-4	168	.	.	.	.	.	.	.	.	18	10.9	1	0.6	.	.	.	.	.	.
		5-9	256	.	.	.	.	.	.	.	.	18	7.1	.	.	.	.	.	.	.	.
		10-14	125	.	.	.	.	.	.	.	.	9	7.4	.	.	.	.	.	.	.	.
		15-20	35	.	.	.	.	.	.	.	.	2	6.3	.	.	.	.	.	.	.	.
Females	**All cases**		**383**	**.**	**.**	**1**	**0.3**	**.**	**.**	**.**	**.**	**38**	**10.0**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
	Age at baseline	<18	92	.	.	.	.	.	.	.	.	8	8.7	.	.	.	.	.	.	.	.
		18-19	33	.	.	.	.	.	.	.	.	4	12.5	.	.	.	.	.	.	.	.
		20-24	98	.	.	.	.	.	.	.	.	9	9.3	.	.	.	.	.	.	.	.
		25-29	91	.	.	1	1.1	.	.	.	.	4	4.4	.	.	.	.	.	.	.	.
		30-34	56	.	.	.	.	.	.	.	.	8	14.3	.	.	.	.	.	.	.	.
		35+	13	.	.	.	.	.	.	.	.	5	38.5	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	47	.	.	.	.	.	.	.	.	7	14.9	.	.	.	.	.	.	.	.
		10-14	137	.	.	.	.	.	.	.	.	10	7.4	.	.	.	.	.	.	.	.
		15-19	118	.	.	1	0.9	.	.	.	.	8	6.9	.	.	.	.	.	.	.	.
		20+	81	.	.	.	.	.	.	.	.	13	16.0	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		1-4	112	.	.	.	.	.	.	.	.	12	10.8	.	.	.	.	.	.	.	.
		5-9	146	.	.	1	0.7	.	.	.	.	13	9.0	.	.	.	.	.	.	.	.
		10-14	95	.	.	.	.	.	.	.	.	11	11.7	.	.	.	.	.	.	.	.
		15-20	23	.	.	.	.	.	.	.	.	2	8.7	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2839**	**1**	**0.0**	**.**	**.**	**.**	**.**	**.**	**.**	**1**	**0.0**	**12**	**0.4**	**.**	**.**	**.**	**.**	**2**	**0.1**
	Age at baseline	<18	55	.	.	.	.	.	.	.	.	.	.	1	1.8	.	.	.	.	.	.
		18-19	54	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	330	.	.	.	.	.	.	.	.	.	.	2	0.6	.	.	.	.	.	.
		25-29	734	.	.	.	.	.	.	.	.	.	.	4	0.6	.	.	.	.	.	.
		30-34	867	.	.	.	.	.	.	.	.	.	.	3	0.4	.	.	.	.	1	0.1
		35+	799	1	0.1	.	.	.	.	.	.	1	0.1	2	0.3	.	.	.	.	1	0.1
	Years since diagnosis	5-9	222	.	.	.	.	.	.	.	.	.	.	3	1.4	.	.	.	.	.	.
		10-14	866	.	.	.	.	.	.	.	.	.	.	2	0.2	.	.	.	.	1	0.1
		15-19	933	1	0.1	.	.	.	.	.	.	.	.	4	0.4	.	.	.	.	1	0.1
		20+	818	.	.	.	.	.	.	.	.	1	0.1	3	0.4	.	.	.	.	.	.
	Age at diagnosis	1-4	70	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	356	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	1029	.	.	.	.	.	.	.	.	.	.	7	0.7	.	.	.	.	.	.
		15-20	1384	1	0.1	.	.	.	.	.	.	1	0.1	5	0.4	.	.	.	.	2	0.1
Males	**All cases**		**1468**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**1**	**0.1**	**8**	**0.6**	**.**	**.**	**.**	**.**	**.**	**.**
	Age at baseline	<18	42	.	.	.	.	.	.	.	.	.	.	1	2.4	.	.	.	.	.	.
		18-19	43	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	210	.	.	.	.	.	.	.	.	.	.	2	1.0	.	.	.	.	.	.
		25-29	402	.	.	.	.	.	.	.	.	.	.	3	0.8	.	.	.	.	.	.
		30-34	433	.	.	.	.	.	.	.	.	.	.	2	0.5	.	.	.	.	.	.
		35+	338	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	127	.	.	.	.	.	.	.	.	.	.	3	2.4	.	.	.	.	.	.
		10-14	440	.	.	.	.	.	.	.	.	.	.	2	0.5	.	.	.	.	.	.
		15-19	495	.	.	.	.	.	.	.	.	.	.	2	0.4	.	.	.	.	.	.
		20+	406	.	.	.	.	.	.	.	.	1	0.2	1	0.2	.	.	.	.	.	.
	Age at diagnosis	1-4	52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	261	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	525	.	.	.	.	.	.	.	.	.	.	5	1.0	.	.	.	.	.	.
		15-20	630	.	.	.	.	.	.	.	.	1	0.2	3	0.5	.	.	.	.	.	.
Females	**All cases**		**1371**	**1**	**0.1**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**4**	**0.3**	**.**	**.**	**.**	**.**	**2**	**0.1**
	Age at baseline	<18	13	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	11	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	120	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	332	.	.	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.
		30-34	434	.	.	.	.	.	.	.	.	.	.	1	0.2	.	.	.	.	1	0.2
		35+	461	1	0.2	.	.	.	.	.	.	.	.	2	0.4	.	.	.	.	1	0.2
	Years since diagnosis	5-9	95	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	426	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.2
		15-19	438	1	0.2	.	.	.	.	.	.	.	.	2	0.5	.	.	.	.	1	0.2
		20+	412	.	.	.	.	.	.	.	.	.	.	2	0.5	.	.	.	.	.	.
	Age at diagnosis	1-4	18	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	95	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	504	.	.	.	.	.	.	.	.	.	.	2	0.4	.	.	.	.	.	.
		15-20	754	1	0.1	.	.	.	.	.	.	.	.	2	0.3	.	.	.	.	2	0.3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1933**	.	.	**1**	**0.1**	.	.	.	.	**209**	**10.9**	**576**	**30.1**	.	.	.	.	.	.
	Age at baseline	<18	200	.	.	.	.	.	.	.	.	25	12.6	65	32.7	.	.	.	.	.	.
		18-19	119	.	.	.	.	.	.	.	.	21	17.8	47	39.8	.	.	.	.	.	.
		20-24	409	.	.	1	0.2	.	.	.	.	39	9.6	118	29.1	.	.	.	.	.	.
		25-29	533	.	.	.	.	.	.	.	.	59	11.2	158	30.2	.	.	.	.	.	.
		30-34	443	.	.	.	.	.	.	.	.	45	10.2	141	32.0	.	.	.	.	.	.
		35+	229	.	.	.	.	.	.	.	.	20	8.8	47	20.8	.	.	.	.	.	.
	Years since diagnosis	5-9	132	.	.	1	0.8	.	.	.	.	15	11.4	40	30.5	.	.	.	.	.	.
		10-14	608	.	.	.	.	.	.	.	.	65	10.8	182	30.2	.	.	.	.	.	.
		15-19	665	.	.	.	.	.	.	.	.	75	11.4	218	33.1	.	.	.	.	.	.
		20+	528	.	.	.	.	.	.	.	.	54	10.3	136	26.1	.	.	.	.	.	.
	Age at diagnosis	<1	12	.	.	.	.	.	.	.	.	3	25.0	3	25.0	.	.	.	.	.	.
		1-4	320	.	.	.	.	.	.	.	.	42	13.3	117	37.3	.	.	.	.	.	.
		5-9	588	.	.	.	.	.	.	.	.	64	10.9	170	29.1	.	.	.	.	.	.
		10-14	604	.	.	1	0.2	.	.	.	.	69	11.5	183	30.5	.	.	.	.	.	.
		15-20	409	.	.	.	.	.	.	.	.	31	7.7	103	25.6	.	.	.	.	.	.
Males	**All cases**		**1304**	.	.	.	.	.	.	.	.	**135**	**10.4**	**366**	**28.3**	.	.	.	.	.	.
	Age at baseline	<18	138	.	.	.	.	.	.	.	.	15	10.9	45	32.8	.	.	.	.	.	.
		18-19	87	.	.	.	.	.	.	.	.	17	19.8	31	36.0	.	.	.	.	.	.
		20-24	268	.	.	.	.	.	.	.	.	24	9.0	74	27.7	.	.	.	.	.	.
		25-29	372	.	.	.	.	.	.	.	.	40	10.9	102	27.9	.	.	.	.	.	.
		30-34	291	.	.	.	.	.	.	.	.	26	9.0	86	29.7	.	.	.	.	.	.
		35+	148	.	.	.	.	.	.	.	.	13	8.8	28	19.0	.	.	.	.	.	.
	Years since diagnosis	5-9	99	.	.	.	.	.	.	.	.	12	12.1	34	34.7	.	.	.	.	.	.
		10-14	412	.	.	.	.	.	.	.	.	43	10.5	117	28.5	.	.	.	.	.	.
		15-19	433	.	.	.	.	.	.	.	.	46	10.7	132	30.7	.	.	.	.	.	.
		20+	360	.	.	.	.	.	.	.	.	34	9.6	83	23.4	.	.	.	.	.	.
	Age at diagnosis	<1	3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	215	.	.	.	.	.	.	.	.	29	13.7	74	35.2	.	.	.	.	.	.
		5-9	411	.	.	.	.	.	.	.	.	41	10.0	114	27.9	.	.	.	.	.	.
		10-14	412	.	.	.	.	.	.	.	.	50	12.1	120	29.1	.	.	.	.	.	.
		15-20	263	.	.	.	.	.	.	.	.	15	5.7	58	22.3	.	.	.	.	.	.
Females	**All cases**		**629**	.	.	**1**	**0.2**	.	.	.	.	**74**	**11.9**	**210**	**33.9**	.	.	.	.	.	.
	Age at baseline	<18	62	.	.	.	.	.	.	.	.	10	16.1	20	32.3	.	.	.	.	.	.
		18-19	32	.	.	.	.	.	.	.	.	4	12.5	16	50.0	.	.	.	.	.	.
		20-24	141	.	.	1	0.7	.	.	.	.	15	10.8	44	31.7	.	.	.	.	.	.
		25-29	161	.	.	.	.	.	.	.	.	19	11.9	56	35.7	.	.	.	.	.	.
		30-34	152	.	.	.	.	.	.	.	.	19	12.6	55	36.4	.	.	.	.	.	.
		35+	81	.	.	.	.	.	.	.	.	7	8.9	19	24.1	.	.	.	.	.	.
	Years since diagnosis	5-9	33	.	.	1	3.0	.	.	.	.	3	9.1	6	18.2	.	.	.	.	.	.
		10-14	196	.	.	.	.	.	.	.	.	22	11.3	65	33.7	.	.	.	.	.	.
		15-19	232	.	.	.	.	.	.	.	.	29	12.7	86	37.7	.	.	.	.	.	.
		20+	168	.	.	.	.	.	.	.	.	20	12.0	53	31.9	.	.	.	.	.	.
	Age at diagnosis	<1	9	.	.	.	.	.	.	.	.	3	33.3	3	33.3	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		1-4	105	.	.	.	.	.	.	.	.	13	12.5	43	41.3	.	.	.	.	.	.
		5-9	177	.	.	.	.	.	.	.	.	23	13.0	56	31.8	.	.	.	.	.	.
		10-14	192	.	.	1	0.5	.	.	.	.	19	10.1	63	33.5	.	.	.	.	.	.
		15-20	146	.	.	.	.	.	.	.	.	16	11.2	45	31.5	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2087**	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at baseline	<18	762	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	276	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	616	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	347	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	69	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	17	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	168	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	674	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	685	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	560	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	305	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	1270	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	436	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	56	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	20	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Males	**All cases**		**924**	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at baseline	<18	370	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	111	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	255	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	152	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	29	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	75	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	306	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	292	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	251	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	152	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	567	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	177	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	20	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Females	**All cases**		**1163**	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at baseline	<18	392	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	165	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	361	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	195	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	40	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	10	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	93	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	368	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	393	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	309	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	153	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	703	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	259	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	36	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	12	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1811**	.	.	.	.	.	.	.	.	**11**	**0.6**	**1**	**0.1**	.	.	.	.	**86**	**4.8**
	Age at baseline	<18	890	.	.	.	.	.	.	.	.	8	0.9	1	0.1	.	.	.	.	59	6.7
		18-19	216	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	6	2.8
		20-24	511	.	.	.	.	.	.	.	.	3	0.6	.	.	.	.	.	.	19	3.7
		25-29	154	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	2	1.3
		30-34	34	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	152	.	.	.	.	.	.	.	.	2	1.3	1	0.7	.	.	.	.	16	10.7
		10-14	559	.	.	.	.	.	.	.	.	5	0.9	.	.	.	.	.	.	38	6.8
		15-19	594	.	.	.	.	.	.	.	.	1	0.2	.	.	.	.	.	.	24	4.1
		20+	506	.	.	.	.	.	.	.	.	3	0.6	.	.	.	.	.	.	8	1.6
	Age at diagnosis	<1	917	.	.	.	.	.	.	.	.	8	0.9	.	.	.	.	.	.	10	1.1
		1-4	713	.	.	.	.	.	.	.	.	3	0.4	1	0.1	.	.	.	.	56	7.9
		5-9	137	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	18	13.4
		10-14	27	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	3.8
		15-20	17	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	5.9
Males	**All cases**		**876**	.	.	.	.	.	.	.	.	**4**	**0.5**	**1**	**0.1**	.	.	.	.	**53**	**6.1**
	Age at baseline	<18	441	.	.	.	.	.	.	.	.	2	0.5	1	0.2	.	.	.	.	40	9.1
		18-19	94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5	5.3
		20-24	259	.	.	.	.	.	.	.	.	2	0.8	.	.	.	.	.	.	7	2.7
		25-29	66	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.6
		30-34	14	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	72	.	.	.	.	.	.	.	.	2	2.8	1	1.4	.	.	.	.	8	11.3
		10-14	275	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	26	9.5
		15-19	284	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	16	5.7
		20+	245	.	.	.	.	.	.	.	.	2	0.8	.	.	.	.	.	.	3	1.2
	Age at diagnosis	<1	472	.	.	.	.	.	.	.	.	2	0.4	.	.	.	.	.	.	8	1.7
		1-4	320	.	.	.	.	.	.	.	.	2	0.6	1	0.3	.	.	.	.	32	10.1
		5-9	68	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13	19.4
		10-14	10	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Females	**All cases**		**935**	.	.	.	.	.	.	.	.	**7**	**0.8**	.	.	.	.	.	.	**33**	**3.6**
	Age at baseline	<18	449	.	.	.	.	.	.	.	.	6	1.3	.	.	.	.	.	.	19	4.3
		18-19	122	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	0.8
		20-24	252	.	.	.	.	.	.	.	.	1	0.4	.	.	.	.	.	.	12	4.8
		25-29	88	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	1.2
		30-34	20	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	80	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	8	10.1
		10-14	284	.	.	.	.	.	.	.	.	5	1.8	.	.	.	.	.	.	12	4.2
		15-19	310	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.	8	2.6
		20+	261	.	.	.	.	.	.	.	.	1	0.4	.	.	.	.	.	.	5	1.9
	Age at diagnosis	<1	445	.	.	.	.	.	.	.	.	6	1.4	.	.	.	.	.	.	2	0.5
		1-4	393	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.	24	6.2
		5-9	69	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	5	7.5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	17	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	6.3
		15-20	11	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	1	9.1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1596**	.	.	.	.	**2**	**0.1**	.	.	**3**	**0.2**	**1**	**0.1**	.	.	.	.	.	.
	Age at baseline	<18	313	.	.	.	.	1	0.3	.	.	2	0.6	.	.	.	.	.	.	.	.
		18-19	115	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	383	.	.	.	.	1	0.3	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	354	.	.	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.
		30-34	267	.	.	.	.	.	.	.	.	1	0.4	.	.	.	.	.	.	.	.
		35+	164	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	165	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	473	.	.	.	.	1	0.2	.	.	2	0.4	.	.	.	.	.	.	.	.
		15-19	499	.	.	.	.	1	0.2	.	.	1	0.2	1	0.2	.	.	.	.	.	.
		20+	459	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	108	.	.	.	.	1	0.9	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	513	.	.	.	.	1	0.2	.	.	2	0.4	.	.	.	.	.	.	.	.
		5-9	361	.	.	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.
		10-14	313	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.	.	.
		15-20	301	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Males	**All cases**		**853**	.	.	.	.	**2**	**0.2**	.	.	**1**	**0.1**	.	.	.	.	.	.	.	.
	Age at baseline	<18	179	.	.	.	.	1	0.6	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	58	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	214	.	.	.	.	1	0.5	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	182	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	141	.	.	.	.	.	.	.	.	1	0.7	.	.	.	.	.	.	.	.
		35+	79	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	89	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	264	.	.	.	.	1	0.4	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	253	.	.	.	.	1	0.4	.	.	1	0.4	.	.	.	.	.	.	.	.
		20+	247	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	44	.	.	.	.	1	2.3	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	298	.	.	.	.	1	0.3	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	203	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	167	.	.	.	.	.	.	.	.	1	0.6	.	.	.	.	.	.	.	.
		15-20	141	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Females	**All cases**		**743**	.	.	.	.	.	.	.	.	**2**	**0.3**	**1**	**0.1**	.	.	.	.	.	.
	Age at baseline	<18	134	.	.	.	.	.	.	.	.	2	1.5	.	.	.	.	.	.	.	.
		18-19	57	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	169	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	172	.	.	.	.	.	.	.	.	.	.	1	0.6	.	.	.	.	.	.
		30-34	126	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	85	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	76	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	209	.	.	.	.	.	.	.	.	2	1.0	.	.	.	.	.	.	.	.
		15-19	246	.	.	.	.	.	.	.	.	.	.	1	0.4	.	.	.	.	.	.
		20+	212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	64	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	215	.	.	.	.	.	.	.	.	2	0.9	.	.	.	.	.	.	.	.
		5-9	158	.	.	.	.	.	.	.	.	.	.	1	0.6	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	146	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	160	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1937**	.	.	.	.	.	.	.	.	**1**	**0.1**	**1**	**0.1**	.	.	.	.	.	.
	Age at baseline	<18	85	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	66	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	360	.	.	.	.	.	.	.	.	1	0.3	1	0.3	.	.	.	.	.	.
		25-29	528	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	521	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	377	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	216	.	.	.	.	.	.	.	.	1	0.5	.	.	.	.	.	.	.	.
		10-14	630	.	.	.	.	.	.	.	.	.	.	1	0.2	.	.	.	.	.	.
		15-19	635	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	456	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	80	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	337	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	776	.	.	.	.	.	.	.	.	.	.	1	0.1	.	.	.	.	.	.
		15-20	736	.	.	.	.	.	.	.	.	1	0.1	.	.	.	.	.	.	.	.
Males	**All cases**		**983**	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at baseline	<18	43	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	33	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	175	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	274	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	258	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	200	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	115	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	319	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	323	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	226	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	41	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	172	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	364	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	402	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Females	**All cases**		**954**	.	.	.	.	.	.	.	.	**1**	**0.1**	**1**	**0.1**	.	.	.	.	.	.
	Age at baseline	<18	42	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	33	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	185	.	.	.	.	.	.	.	.	1	0.5	1	0.5	.	.	.	.	.	.
		25-29	254	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	263	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	177	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	101	.	.	.	.	.	.	.	.	1	1.0	.	.	.	.	.	.	.	.
		10-14	311	.	.	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.
		15-19	312	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	230	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	39	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	165	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	412	.	.	.	.	.	.	.	.	.	.	1	0.2	.	.	.	.	.	.
		15-20	334	.	.	.	.	.	.	.	.	1	0.3	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**686**	.	.	.	.	.	.	.	.	.	.	**1**	**0.1**	.	.	.	.	.	.
	Age at baseline	<18	54	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	33	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	157	.	.	.	.	.	.	.	.	.	.	1	0.6	.	.	.	.	.	.
		25-29	193	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	154	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	95	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	91	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	231	.	.	.	.	.	.	.	.	.	.	1	0.4	.	.	.	.	.	.
		15-19	214	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	150	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	50	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	169	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	258	.	.	.	.	.	.	.	.	.	.	1	0.4	.	.	.	.	.	.
		15-20	205	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Males	**All cases**		**354**	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at baseline	<18	24	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	17	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	79	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	99	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	83	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	52	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	49	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	109	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	116	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	80	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	26	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	83	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	136	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	107	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Females	**All cases**		**332**	.	.	.	.	.	.	.	.	.	.	**1**	**0.3**	.	.	.	.	.	.
	Age at baseline	<18	30	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	16	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	78	.	.	.	.	.	.	.	.	.	.	1	1.3	.	.	.	.	.	.
		25-29	94	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	71	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	43	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	42	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	122	.	.	.	.	.	.	.	.	.	.	1	0.8	.	.	.	.	.	.
		15-19	98	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	70	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	24	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	86	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	122	.	.	.	.	.	.	.	.	.	.	1	0.8	.	.	.	.	.	.
		15-20	98	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1154**	.	.	.	.	.	.	.	.	**1**	**0.1**	.	.	.	.	.	.	.	.
	Age at baseline	<18	25	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	27	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	184	.	.	.	.	.	.	.	.	1	0.5	.	.	.	.	.	.	.	.
		25-29	317	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	340	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	261	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	119	.	.	.	.	.	.	.	.	1	0.8	.	.	.	.	.	.	.	.
		10-14	362	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	392	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	281	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	1-4	21	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	151	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	492	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	490	.	.	.	.	.	.	.	.	1	0.2	.	.	.	.	.	.	.	.
Males	**All cases**		**581**	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at baseline	<18	18	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	12	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	86	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		25-29	165	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	161	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	139	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	64	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	191	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	192	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	134	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	1-4	11	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	76	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	221	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	273	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Females	**All cases**		**573**	.	.	.	.	.	.	.	.	**1**	**0.2**	.	.	.	.	.	.	.	.
	Age at baseline	<18	7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		18-19	15	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	98	.	.	.	.	.	.	.	.	1	1.0	.	.	.	.	.	.	.	.
		25-29	152	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		30-34	179	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		35+	122	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	55	.	.	.	.	.	.	.	.	1	1.8	.	.	.	.	.	.	.	.
		10-14	171	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-19	200	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20+	147	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Age at diagnosis	1-4	10	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		5-9	75	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	271	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		15-20	217	.	.	.	.	.	.	.	.	1	0.5	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.